SYGNIS is granted the European and US patent for a very versatile and efficient drug screening platform
18-Jan-2013
- Germany
Protein-protein interactions falls within the scope of proteomics, a field that is growing in importance for research into new customized drugs. SYGNIS’ new platform can be used to improve the characterization of new drugs in development and identification of new therapeutic targets. SYGNIS’ technology will increase the potential for generating better drugs within the customized drug development field.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.